Basilea Pharmaceutica AG Logo

Basilea Pharmaceutica AG

Develops & commercializes anti-infectives for severe bacterial & fungal infections.

BSLN | SW

Overview

Corporate Details

ISIN(s):
CH0011432447 (+1 more)
LEI:
391200TTZP8EIPSJ5J20
Country:
Switzerland
Address:
Henric Petri-Strasse 35, 4051 Basel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines for severe bacterial and fungal infections. The company's key marketed products are the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole). Basilea manages the full drug development lifecycle, from research through clinical trials to market launch, aiming to establish its products as global brands. Founded in 2000 as a spin-off from F. Hoffmann-La Roche, the company leverages its expertise to address critical medical needs in the anti-infectives field.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 02:00
Capital/Financing Update
Basilea awarded BARDA contract for the development of novel oral phase 3-ready …
English 8.7 KB
2025-09-25 02:00
Capital/Financing Update
Basilea schliesst eine Fördervereinbarung mit BARDA für die Entwicklung des Pha…
German 10.0 KB
2025-09-16 02:00
Regulatory News Service
Basilea receives USD 25 million funding under BARDA agreement to continue to ad…
English 11.0 KB
2025-09-16 02:00
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 25 Mio. für die weitere E…
German 12.7 KB
2025-08-19 02:00
Earnings Release
Basilea on track with strong 2025 half-year results
English 19.5 KB
2025-08-19 02:00
Earnings Release
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
German 21.4 KB
2025-08-14 02:00
M&A Activity
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
English 11.4 KB
2025-08-14 02:00
M&A Activity
Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das…
German 12.9 KB
2025-07-08 02:00
Regulatory News Service
Basilea receives USD 39 million funding under BARDA agreement to continue to ad…
English 11.2 KB
2025-07-08 02:00
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere E…
German 13.0 KB
2025-02-18 01:00
Earnings Release
Basilea reports strong 2024 full-year results with significant increase in reve…
English 19.9 KB
2025-02-18 01:00
Earnings Release
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anst…
German 23.1 KB
2024-12-23 01:00
Regulatory News Service
Basilea is awarded additional CARB-X funding to develop new drug candidate from…
English 7.8 KB
2024-12-23 01:00
Regulatory News Service
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamen…
German 9.2 KB
2024-12-16 01:00
M&A Activity
Basilea announces agreement with Innoviva Specialty Therapeutics for the commer…
English 9.4 KB

Automate Your Workflow. Get a real-time feed of all Basilea Pharmaceutica AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Basilea Pharmaceutica AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-21 N/A Executive member Sell None 27,000.00 CHF
2025-04-30 N/A Executive member Sell None 17,600.00 CHF
2025-04-23 N/A Executive member Sell None 57,396.20 CHF
2025-04-23 N/A Non-Executive member Sell None 30,331.00 CHF
2025-04-17 N/A Executive member Sell None 173,479.91 CHF
2025-04-17 N/A Executive member Sell None 118,568.67 CHF
2025-04-17 N/A Executive member Sell None 41,255.63 CHF
2024-10-28 N/A Executive member Sell None 22,500.00 CHF
2024-04-25 N/A Executive member Sell None 79,966.26 CHF
2024-04-24 N/A Executive member Sell None 23,128.70 CHF

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.